EBMT 2022 | The importance of public-private partnerships in hematology-oncology

Guillermo Sanz • 21 Mar 2022

EBMT 2022

General

Guillermo Sanz, MD, PhD, Hospital Universitario y Politécnico La Fe, Valencia, Spain, discusses private-public partnerships in the field of hematology-oncology. Prof. Sanz explains that this partnership allows companies to compare their clinical trial results with those achieved in real-world settings. In addition to this, the partnership is essential because nowadays there are multiple stakeholders, such as universities and pharmaceutical companies, interested and involved in hematological malignancies. Prof. Sanz further explains that these partnerships are beneficial to patients and the current healthcare system. The benefit to the patients comes from a reduction in the cost of clinical trials which ultimately leads to a lower cost for drug development. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.